$BDSX Cashflow Statement | Understand Stock

$BDSX

$21.95 +$0.69 (3.25%) Close

$BDSX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities
Depreciation and amortization
Amortization of lease right-of-use assets
(Accretion) reduction of lease right-of-use assets
Accretion of lease right-of-use assets
Loss on extinguishment of liabilities
Share-based compensation expense
Change in contingent consideration
Provision for doubtful accounts
Provision for credit losses
Accrued interest, amortization of debt issuance costs and other
Inventory excess and obsolescence
Impairment loss on intangible assets

Changes in operating assets and liabilities:
Accounts receivable
Other current assets
Other long-term assets
Accounts payable and other accrued liabilities
Deferred revenue
Contingent consideration
Tenant improvement allowances received
Current and long-term operating lease liabilities
Net cash, cash equivalents, and restricted cash used in operating activities
Cash flows from investing activities
Purchase of property and equipment
Patent costs and intangible asset acquisition, net
Net cash, cash equivalents, and restricted cash used in investing activities
Cash flows from financing activities
Proceeds from the issuance of common stock
Proceeds from issuance of common stock under employee stock purchase plan
Proceeds from exercise of stock options
Payment of contingent consideration
Proceeds from term loan and notes payable
Payment of debt issuance costs
Deferred offering costs
Equity financing costs
Other
Net cash, cash equivalents, and restricted cash provided by financing activities

Net decrease in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash ‑ beginning of period
Cash, cash equivalents, and restricted cash ‑ end of period
Supplemental cash flow information:
Common stock issued for deferred offering costs
Deferred offering costs amortized against Additional paid-in capital
Debt issuance costs included in accounts payable and other accrued liabilities
Equity financing costs included in accounts payable and other accrued liabilities
Issuance of Perceptive Warrants
Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842
Operating lease right-of-use asset obtained in exchange for lease liabilities
Finance lease right-of-use assets obtained in exchange for lease liabilities
Cash paid for interest
Reclassification of warrant liability to additional paid-in capital
Non-cash debt issuance costs included in Accrued liabilities
Change in fair value of Perceptive Warrants
Reclassification of Tranche C warrants to additional paid-in capital
Purchases of property & equipment included in accounts payable and accrued liabilities

Comments